Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baclofen to Prevent Agitation in Alcohol Addicted Patients in ICU
NCT02723383Phase 3Completed
- Sponsor
- CHU de Nantes
- Start
- Jun 2016
- Primary completion
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of baclofen in alcohol withdrawal syndrome (AWS), sponsored by CHU de Nantes. Started Jun 2016; status: completed.
02
Drugs
baclofen
03
Conditions
alcohol withdrawal syndrome (AWS)
Beyond the preview
Go deeper on NCT02723383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02723383.